Recent capital raise and warrant exercises extend cash runway through second quarter of 2027
Conference call begins at
Second Quarter Results and Recent Highlights:
- Net sales were
$2.0 million in the second quarter, a 14% increase compared with the prior-year period;U.S . revenue increased 17% - Net sales for the first six months of 2026 were
$4.4 million , a 20% increase compared with the prior-year period;U.S . revenue increased 24% - Gross margin in the second quarter improved to 76%, compared with 56% in the prior-year quarter, reflecting improved pricing, product mix, and the transition to contract manufacturing
- Sold nine consoles during the second quarter and 24 during the first half of 2026, compared with five during the first half of 2025, expanding the installed base for future circuit utilization
- First-half revenue increased across all core customer categories compared with the prior-year period, led by a 29% increase in pediatrics, 28% in critical care, and 27% in heart failure.
U.S . revenue growth outpaced the total Company average, which included lower international, service, and rental revenue. - Raised
$6.0 million in gross proceeds through a June registered direct offering - Subsequent to
June 30, 2026 , raised approximately$6.7 million in gross proceeds from a July financing and warrant exercises, strengthening the Company’s cash position and simplifying its capitalization structure - Advanced the proposed Aquadex label expansion to patients weighing 5 kilograms or more, from patients weighing 20 kilograms or more, following a successful
U.S. Food and Drug Administration pre-submission meeting - Appointed
Mike McCormick as President and Chief Executive Officer, effectiveJune 30, 2026
The second quarter demonstrated continued year-over-year growth, meaningful gross-margin improvement and progress across Nuwellis’ commercial and strategic priorities. The Company enters its next phase focused on increasing the installed based and utilization of Aquadex, building recurring circuit revenue, expanding its position in pediatrics and critical care, and selectively advancing technologies that strengthen its broader cardiorenal platform.
“Nuwellis has an established commercial foundation with differentiated strength in pediatrics and momentum in critical care. Our straightforward objective is to grow recurring revenue, improve operating leverage, and position Nuwellis as the leading precision fluid management company across the cardiorenal continuum,” said
Second Quarter 2026 Financial Results
Revenue for the second quarter of 2026 was
The Company sold nine consoles during the second quarter, compared with three during the second quarter of 2025. The expanding installed base is expected to bolster growth in recurring circuit revenue, which remains the Company's primary driver of long-term growth.
Gross margin for the second quarter of 2026 was 76%, compared with 56% in the prior-year quarter. The improvement reflected pricing adjustments implemented in 2025, favorable product mix, and our successful transition to contract manufacturing.
Operating expenses were approximately
As of
Webcast and Conference Call Information
The Company will host a conference call and webcast at
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com/.
Alternatively, the live conference call may be accessed by dialing (833) 316-1983 or (785) 838-9310 and using conference ID NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page.
About Aquadex
The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
CORE IR
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||||
2026 | |||||||||
| ASSETS | (Unaudited) | ||||||||
| Current assets | |||||||||
| Cash and cash equivalents | $ | 3,922 | $ | 1,085 | |||||
| Accounts receivable | 1,545 | 1,493 | |||||||
| Inventories, net | 1,742 | 1,910 | |||||||
| Other current assets | 690 | 698 | |||||||
| Total current assets | 7,899 | 5,186 | |||||||
| Property, plant and equipment, net | 347 | 368 | |||||||
| Operating lease right-of-use asset | 179 | 293 | |||||||
| Intangible assets, net | 102 | — | |||||||
| Other assets | 599 | 271 | |||||||
| TOTAL ASSETS | $ | 9,126 | $ | 6,118 | |||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||||
| Current liabilities | |||||||||
| Accounts payable and accrued liabilities | $ | 2,896 | $ | 2,226 | |||||
| Accrued compensation | 731 | 460 | |||||||
| Current portion of operating lease liability | 200 | 261 | |||||||
| Deferred consideration from Rendiatech acquisition, current | 113 | — | |||||||
| Other current liabilities | 68 | 85 | |||||||
| Total current liabilities | 4,008 | 3,032 | |||||||
| Deferred consideration from Rendiatech acquisition, non-current | 200 | — | |||||||
| Warrant liabilities | 6,963 | 389 | |||||||
| Operating lease liability | — | 67 | |||||||
| Total liabilities | 11,171 | 3,488 | |||||||
| Commitments and contingencies | |||||||||
| Mezzanine Equity Series J Convertible Preferred Stock as of | 10 | 6 | |||||||
| Stockholders’ equity (deficit) | |||||||||
| Series A junior participating preferred stock as of | — | — | |||||||
| Series F convertible preferred stock as of | — | — | |||||||
| Series F-1 convertible preferred stock as of | — | — | |||||||
| Preferred stock as of | — | — | |||||||
| Common stock as of 574,455 and 48,178, respectively | — | — | |||||||
| Additional paid-in capital | 323,618 | 318,928 | |||||||
| Accumulated other comprehensive income: | |||||||||
| Foreign currency translation adjustment | 8 | 8 | |||||||
| Accumulated deficit | (325,681 | ) | (316,312 | ) | |||||
| Total stockholders’ equity (deficit) | (2,055 | ) | 2,624 | ||||||
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY(DEFICIT) | $ | 9,126 | $ | 6,118 | |||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | |||||||||||||||||||||
| Three months ended | Six months ended | ||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||
| Net sales | $ | 1,969 | $ | 1,725 | $ | 4,372 | $ | 3,629 | |||||||||||||
| Cost of goods sold | 471 | 767 | 1,190 | 1,604 | |||||||||||||||||
| Gross profit | 1,498 | 958 | 3,182 | 2,025 | |||||||||||||||||
| Operating expenses: | |||||||||||||||||||||
| Selling, general and administrative | 3,725 | 3,189 | 8,249 | 6,766 | |||||||||||||||||
| Research and development | 942 | 675 | 2,670 | 1,225 | |||||||||||||||||
| Total operating expenses | 4,667 | 3,864 | 10,919 | 7,991 | |||||||||||||||||
| Loss from operations | (3,169 | ) | (2,906 | ) | (7,737 | ) | (5,966 | ) | |||||||||||||
| Other income | 7 | 10 | 8 | 17 | |||||||||||||||||
| Financing expense | (6,077 | ) | (10,553 | ) | (6,077 | ) | (10,553 | ) | |||||||||||||
| Change in fair value of warrant liabilities | 4,411 | 900 | 4,437 | 940 | |||||||||||||||||
| Loss before income taxes | (4,828 | ) | (12,549 | ) | (9,369 | ) | (15,562 | ) | |||||||||||||
| Income tax expense | - | (4 | ) | - | (5 | ) | |||||||||||||||
| Net loss | $ | (4,828 | ) | $ | (12,553 | ) | $ | (9,369 | ) | $ | (15,567 | ) | |||||||||
| Deemed dividend attributable to Series J Convertible Preferred Stock | 1 | 1 | 3 | 2 | |||||||||||||||||
| Net loss attributable to common shareholders | $ | (4,827 | ) | $ | (12,552 | ) | $ | (9,366 | ) | $ | (15,565 | ) | |||||||||
| Basic and diluted loss per share | $ | (26.64 | ) | $ | (2,134.19 | ) | $ | (77.90 | ) | $ | (3,514.87 | ) | |||||||||
| Weighted average shares outstanding – basic and diluted | 181,243 | 5,881 | 120,263 | 4,428 | |||||||||||||||||
| Other comprehensive loss: | |||||||||||||||||||||
| Net Loss | $ | (4,828 | ) | $ | (12,553 | ) | $ | (9,369 | ) | $ | (15,567 | ) | |||||||||
| Foreign currency translation adjustments | - | (5 | ) | - | (7 | ) | |||||||||||||||
| Total comprehensive loss | $ | (4,828 | ) | $ | (12,558 | ) | $ | (9,369 | ) | $ | (15,574 | ) | |||||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | |||||||
| Six Months ended | |||||||
| 2026 | 2025 | ||||||
| Operating Activities: | |||||||
| Net loss | $ | (9,369 | ) | $ | (15,567 | ) | |
| Adjustments to reconcile net loss to cash flows used in operating activities: | |||||||
| Depreciation and amortization | 75 | 123 | |||||
| Stock-based compensation expense | 47 | 84 | |||||
| Change in fair value of warrant liabilities | (4,437 | ) | (940 | ) | |||
| Financing expense | 6,077 | 10,553 | |||||
| Non-cash IP R&D from Rendiatech acquisition | 757 | - | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (52 | ) | 534 | ||||
| Inventory, net | 218 | (310 | ) | ||||
| Other current assets | 8 | (430 | ) | ||||
| Other assets | (213 | ) | 106 | ||||
| Other liabilities | (144 | ) | (74 | ) | |||
| Accounts payable and accrued expenses | 746 | 1,288 | |||||
| Net cash used in operating activities | (6,287 | ) | (4,633 | ) | |||
| Investing Activities: | |||||||
| Purchases of property and equipment | (39 | ) | (4 | ) | |||
| Purchase of intangible assets | (90 | ) | - | ||||
| Cash paid for acquisition of Rendiatech, net of cash acquired | (164 | ) | - | ||||
| Net cash used in investing activities | (293 | ) | (4 | ) | |||
| Financing Activities: | |||||||
| Proceeds from issuance of common stock and warrants, net | 9,363 | 3,999 | |||||
| Issuance of common stock from ATM, net | 55 | ||||||
| Net cash provided by financing activities | 9,418 | 3,999 | |||||
| Effect of exchange rate changes on cash | - | (7 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 2,838 | (645 | ) | ||||
| Cash and cash equivalents, and restricted cash - beginning of period | 1,190 | 5,095 | |||||
| Cash and cash equivalents, and restricted cash - end of period | $ | 4,028 | $ | 4,450 | |||
| Supplemental cash flow information | |||||||
| Common stock issued as consideration in asset acquisition | $ | 162 | $ | - | |||
| Issuance of common stock for conversion of Series F-1 Preferred Stock | $ | - | $ | 1,100 | |||
| Deferred costs issued as consideration in asset acquisition | $ | 313 | $ | - | |||
| Deemed dividend on Series J Preferred Stock | $ | 3 | $ | 2 | |||
